| Patent Number |
Title Of Patent |
Date Issued |
| 6103693 |
Method for isolation of highly pure von willebrand factor |
August 15, 2000 |
| The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising b |
| 6100061 |
Recombinant cell clone having increased stability in serum- and protein-free medium and a method |
August 8, 2000 |
| Disclosed are a stable recombinant cell clone which is stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means |
| 6005077 |
Use of von willebrand factor and pharmaceutical formulation |
December 21, 1999 |
| The invention relates to the use of von Willebrand Factor (vWF) with a prolonged biological half-life for the production of a preparation for stabilization of blood coagulation Factor VIII (FVIII:C) in a mammal. Additionally, a pharmaceutical preparation is provided comprising a biol |
| 5962405 |
Storage-stable fibrinogen preparations |
October 5, 1999 |
| The invention relates to storage-stable fibrinogen preparations for preparing concentrated fibrinogen solution for use as a tissue adhesive or for preparing fibrinogen solutions for other uses, for example, for infusion purposes. The fibrinogen preparations are characterized in that(i) t |
| 5892005 |
High molecular and low molecular fractions of von willebrand factor |
April 6, 1999 |
| The invention provides high and low molecular weight fraction of von Willebrand Factor (vWF), which can be obtained by absorbing vWF to a heparin affinity support followed by eluting the vWF at differing salt concentrations. |
| 5883078 |
Hemostyptic and tissue adhesive |
March 16, 1999 |
| A stable tissue adhesive is described which comprises fibrinogen and an activator or pro-activator of prothrombin, wherein its content of prothrombin present in blood is less than 5 units/g fibrinogen. This tissue adhesive can be present as a liquid or dry preparation and can optiona |
| 5880265 |
Method for isolation of highly pure von willebrand factor |
March 9, 1999 |
| The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising b |
| 5877152 |
Method for isolation of highly pure von Willebrand Factor |
March 2, 1999 |
| The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising b |
| 5872099 |
High molecular and low molecular fractions of von Willebrand Factor |
February 16, 1999 |
| The present invention relates to a method for separation of vWF into high molecular vWF and low molecular vWF which is characterized in that vWF is bound to an affinity support and is then eluted at different salt concentrations. |
| 5869617 |
High and low molecular weight fractions of von Willebrand Factor and preparations of same |
February 9, 1999 |
| The invention provides high and low molecular weight fraction of von Willebrand Factor (vWF), which can be obtained by absorbing vWF to a heparin affinity support followed by eluting the vWF at differing salt concentrations The low molecular weight fraction is predominantly dimers an |
| 5866122 |
Pharmaceutical preparation for treating blood coagulation disorders |
February 2, 1999 |
| There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component. |
| 5864016 |
Blood product, a method of producing the same and a method of determining the virus inactivation |
January 26, 1999 |
| A blood product, exclusive of albumin, inactivated relative to infectious agents, the blood product conforming to a total virus reduction factor of at least 40, having a biological acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents, th |
| 5858658 |
Method of quantitating genomic DNA |
January 12, 1999 |
| A method of quantitating genomic DNA in a sample is provided. The method comprises the steps of adding to the sample a given amount of at least one nucleic acid as an internal standard, wherein the standard nucleic acid differs from the genomic DNA to be quantified in at least one detect |
| 5854403 |
Method for isolation of highly pure von Willebrand Factor |
December 29, 1998 |
| The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising b |
| 5833984 |
Composition and method for preventing and treating inflammation with Immunoglobulin A |
November 10, 1998 |
| Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as an |
| 5830467 |
Pharmaceutical preparation containing protein C and a thrombolytically active substance |
November 3, 1998 |
| A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy. |
| 5829634 |
Method of discharging a frozen blood product |
November 3, 1998 |
| A method and an apparatus for discharging a frozen blood product from a container, wherein, for automating purposes, the surface layer of the frozen blood product on the container wall is slightly thawed by heating from outside, whereby a liquid film is formed between the ice core and th |
| 5827818 |
Agent for subcutaneous administration of protein C |
October 27, 1998 |
| The invention relates to a pharmaceutical agent which is suitable for subcutaneous injection of protein C, wherein it comprises protein C and a pharmaceutically acceptable carrier. |
| 5808000 |
Virus-safe monomeric human immunoglobulin A and methods for its production |
September 15, 1998 |
| A virus-safe monomeric human IgA is described which is essentially free of IgG. The IgA according to the invention is obtainable according to a process in which (a) an IgA-containing fraction is subjected to a purification such that a monomeric IgA which is essentially free of IgG is |
| 5804181 |
Pharmaceutical preparation for the prevention and treatment of blood coagulation disorders |
September 8, 1998 |
| A pharmaceutical preparation for the prevention and treatment of blood coagulation disorders is described which is characterized in that it comprises Factor V as a native protein, derivative and/or fragment thereof and Protein S in suitable pharmaceutical carrier. |
| 5804159 |
Antiplasma animal model |
September 8, 1998 |
| There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotti |
| 5792623 |
Method for producing activated blood factors with a protease and a detergent |
August 11, 1998 |
| Proenzymes or proforms of blood factors can be cleaved in the presence of a detergent or a chaotropic substance to produce active blood factors selected from the group consisting of Factor Va, Factor VIIa, Factor VIIIa, Factor IXa, Factor Xa, Factor XIa, Factor XIIa, Factor XIIIa and |
| 5789153 |
Method of quantitating nucleic acid |
August 4, 1998 |
| There is disclosed a method of quantitating nucleic acids in a sample by using nucleic acid amplification, wherein, prior to the amplification step, a given amount of a known nucleic acid molecule is added to the sample as internal standard, which standard nucleic acid molecule differs |
| 5776452 |
Thrombosis agent |
July 7, 1998 |
| The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states. |
| 5770212 |
Recombinant poxviruses with foreign DNA in essential regions |
June 23, 1998 |
| Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. |
| 5770199 |
Method for virus inactivation in the presence of polyalkylene glycol as well as the pharmaceutic |
June 23, 1998 |
| The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps:a) addition of a polyether and a |
| 5766882 |
recombinant poxviruses with foreign DNA in essential regions |
June 16, 1998 |
| Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. |
| 5733885 |
Method of producing a virus-safe biological preparation |
March 31, 1998 |
| In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, pr |
| 5719051 |
Perfusion system and a method for the large scale production of virus or virus antigen |
February 17, 1998 |
| The invention resides in a matrix, i.e. in a carrier material, with human or animal cells adherently bound thereto, the cells being infected with virus. It has shown that surface-dependent cells suitable for virus propagation remain adherently bound to a matrix even in the virus-infected |
| 5714370 |
Thrombin and method of producing the same |
February 3, 1998 |
| A thrombin of human or animal origin is free of infectious agents and is produced by activation of prothrombin subjected to a heat treatment for the inactivation of infectious agents. |
| 5698677 |
Stable preparation for the treatment of blood coagulation disorders |
December 16, 1997 |
| The invention relates to a stable preparation which comprises a protein that is bound in and/or on lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the tre |
| 5670367 |
Recombinant fowlpox virus |
September 23, 1997 |
| An improved method is described to prepare recombinant fowlpox virus for the expression of proteins or for use as a vaccine. The new method uses for the insertion of foreign DNA an intergenic region which is located between the FPV thymidine kinase (tk)gene and the 3'-open reading frame. |
| 5665067 |
Apparatus for applying a multiple-component tissue adhesive |
September 9, 1997 |
| There is disclosed an apparatus for applying a multiple component tissue adhesive, which apparatus has component conveying channels for the components of the tissue adhesive, extending in a one-piece construction part from a connecting part to a delivery part, and a gas conveying cha |
| 5639730 |
Method of producing a virus-safe biological preparation |
June 17, 1997 |
| In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, pr |
| 5633350 |
Method for the isolation and purification of vitamin K-dependent proteins |
May 27, 1997 |
| A method for the separation of vitamin K-dependent proteins from non-vitamin K-dependent accompanying proteins is described wherein the method is characterized in that at least anion exchange chromatography and optionally affinity chromatography is carried out as well. The method is |
| 5614405 |
Method of determining the virus inactivation capacity of an inactivation treatment |
March 25, 1997 |
| This invention is directed to a method of evaluating viral reduction capability of a viral inactivation step in a viral inactivation procedure. The method requires spiking a biological product with a virus more than once during the viral inactivation step so that a virus reduction factor |
| 5610147 |
Virus-safe blood coagulation factor XIII preparation |
March 11, 1997 |
| The present invention relates to a virus-safe blood coagulation factor XIII preparation, which is obtained by heating an aqueous solution containing the blood coagulation factor XIII having a specific activity of at least 2 U/mg of total protein, wherein the solution containing less than |
| 5608038 |
Highly concentrated immunoglobulin preparation and method for its production |
March 4, 1997 |
| A stable, highly concentrated intravenously tolerable immunoglobulin preparation is described having an immunoglobulin content from 13.5 to 17.5% (w/v), an osmolarity from 250 to 600 mOs/l and a viscosity of no more than 9 cP. The immunoglobulin preparation possesses an exceptional i |
| 5597800 |
Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia |
January 28, 1997 |
| A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to h |
| 5593968 |
Virus-inactivated factor Xa preparation |
January 14, 1997 |
| A virus-inactivated Factor-Xa preparation with at least 100 units coagulation factor activity per mg protein is described, wherein this preparation is produced by activation of a corresponding starting material and subsequent treatment for the inactivation of infectious agents, parti |
| 5580962 |
Parenterally administrable drug having thrombolytic activity and containing protein C |
December 3, 1996 |
| A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C. |
| 5576175 |
Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
November 19, 1996 |
| There is disclosed a complex comprised of an insoluble polymer carrier to which monomeric human albumin is covalently bound and of a pre-S hepatitis B surface antigen bound in an elutable form to the monomeric human albumin by its pre-S(2)- and/or pre-S(1)-region. This complex may be use |
| 5571786 |
Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparati |
November 5, 1996 |
| There is disclosed the use of protein C and/or the activation peptide of protein C for preparing a pharmaceutical preparation having anti-nociceptive activity. This pharmaceutical preparation is useful in the treatment of painful conditions caused by acute or chronic inflammatory pro |
| 5550051 |
Avian embryo cell aggregate biomass for producing virus/virus antigen and method for producing v |
August 27, 1996 |
| The invention relates to a biomass for producing virus/virus antigen, which consists of cell aggregates of avian embryo cells having diameters of between 100 .mu.m and 1,000 .mu.m. The biomass according to the invention has a high metabolic activity in suspension in the culture medium an |
| 5549893 |
Use of protein C in the treatment of purpura fulminans |
August 27, 1996 |
| There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory disturbances, in particular with the proviso that the drug does not contain any immunoglobulin |
| 5540666 |
Cannula shield and injection syringe system |
July 30, 1996 |
| There is disclosed an injection syringe assembly comprising a cannula module including a two-part cannula shield device having a separate front cap, as well as a latched-in cannula holder in which a cannula is glued. In the mounted state, a plug-like cannula seal is received in the front |
| 5530103 |
Method for the purification of PC protein from Borrelia burgdorferi |
June 25, 1996 |
| A method of purifying B. burgdorferi proteins comprising the steps of (a) disrupting a B. burgdorferi cell and fractionating the disrupted cell into membrane and cytoplasmic components; (b) resuspending the membrane component in a non-denaturing detergent thereby producing a solubilized |
| 5529905 |
Method of assaying plasma proteins with prothrombin fragments |
June 25, 1996 |
| There is disclosed the use of prothrombin fragments, preferably of human prothrombin fragments, having a thrombin-like activity, in particular of meizothrombin, meizo thrombin (desF1), or mixtures thereof, for diagnostic purposes for assaying thrombin substrates as well as a reagent cont |
| 5520912 |
Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys |
May 28, 1996 |
| A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to h |
| 5445953 |
Direct molecular cloning of a modified poxvirus genome |
August 29, 1995 |
| A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecu |
